IndustryCompany release

CorMedix agrees to buy Heron Therapeutics' assets, adding four hospital products

🇺🇸 CorMedix Inc. (CRMD) · Mon 09 Nov 2026

CorMedix will acquire substantially all of Heron's assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, for cash, shares and contingent earn-outs, with closing expected in Q1 2027.

CorMedix and Heron Therapeutics announced on 9 November 2026 that they have signed a definitive asset purchase agreement. Under it, CorMedix will acquire substantially all of Heron's assets. These include four marketed products: ZYNRELEF, APONVIE, CINVANTI and SUSTOL.

The portfolio covers postoperative pain, postoperative nausea and vomiting, and chemotherapy-induced nausea and vomiting. CorMedix's announcement headlines the deal at about $222.6 million upfront.

The consideration has three parts: $145 million in cash, 14,583,333 CorMedix shares, and up to $55 million in earn-out payments plus royalties. CorMedix plans to fund part of the transaction with a $75 million draw on a new Pharmakon term loan.

Closing is expected in the first quarter of 2027. It remains subject to approval by Heron stockholders and to clearance under the Hart-Scott-Rodino Act, the US antitrust pre-merger review regime.

What it means for your team

  • Teams working with Heron's four products should expect ownership changes if the deal closes. Typically this means transferring regulatory filings and pharmacovigilance and quality arrangements to the buyer, though the source gives no details on timing or process.
  • Market-access and commercial teams at hospitals and payers should watch for any change in contracting counterparties after closing, expected in Q1 2027.
  • Completion depends on Heron stockholder approval and Hart-Scott-Rodino clearance, so the timetable could change.

Company's press release (SEC filing): CorMedix Inc. ↗

Article written by VigiEye from the official source (CorMedix Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →